Antibiotics

Definition and Overview

What Are Antibiotics?

Antibiotics: chemical substances produced by microorganisms or synthetically derived. Function: inhibit or kill bacteria. Scope: primarily target prokaryotic cells, minimal eukaryotic impact. Purpose: treat bacterial infections, prevent bacterial proliferation.

Scope in Medical Biotechnology

Role: cornerstone in infectious disease management. Integration: biotech advances optimize production, modification, and delivery. Impact: reduced mortality, enhanced quality of life globally.

Terminology Clarification

Misnomer: antibiotics vs antimicrobials. Antibiotics: specifically bactericidal or bacteriostatic agents. Antimicrobials: broader, include antifungals, antivirals, antiparasitics.

"Antibiotics revolutionized medicine by transforming fatal infections into manageable conditions." -- Alexander Fleming

Historical Development

Early Observations

Ancient use: mold-infested bread for wound treatment documented in Egypt, China. Pre-modern empirical knowledge of antimicrobial properties.

Discovery of Penicillin

1928: Alexander Fleming identified Penicillium notatum secreting antibacterial compound. Significance: first true antibiotic, marked antibiotic era inception.

Expansion of Antibiotic Classes

1930s-1960s: discovery of sulfonamides, aminoglycosides, tetracyclines, macrolides, cephalosporins. Industrial-scale production initiated. Acceleration of pharmaceutical research.

Classification of Antibiotics

Based on Chemical Structure

β-lactams: penicillins, cephalosporins, carbapenems. Macrolides: erythromycin, azithromycin. Aminoglycosides: streptomycin, gentamicin. Tetracyclines, glycopeptides, quinolones, sulfonamides.

Based on Spectrum of Activity

Narrow-spectrum: target specific bacteria (e.g. penicillin G). Broad-spectrum: effective against multiple bacterial groups (e.g. tetracycline).

Based on Mode of Action

Bactericidal: kill bacteria (e.g. β-lactams). Bacteriostatic: inhibit growth (e.g. chloramphenicol).

Mechanisms of Action

Inhibition of Cell Wall Synthesis

Target: peptidoglycan cross-linking enzymes (transpeptidases). Effect: weakened cell wall, osmotic lysis. Examples: penicillins, cephalosporins.

Protein Synthesis Inhibition

Target: bacterial ribosomes (30S or 50S subunits). Outcome: impaired translation, halted bacterial growth. Examples: tetracyclines (30S), macrolides (50S).

DNA Replication Interference

Target: DNA gyrase, topoisomerase IV. Consequence: inhibition of replication and transcription. Example: fluoroquinolones.

Metabolic Pathway Disruption

Target: folic acid synthesis enzymes. Result: impaired nucleotide biosynthesis. Example: sulfonamides.

Mechanism Summary:1. Cell wall synthesis inhibition2. Protein synthesis disruption3. Nucleic acid synthesis interference4. Metabolic pathway inhibition5. Membrane integrity compromise (polymyxins)

Natural and Synthetic Sources

Natural Producers

Primary sources: soil microorganisms. Actinomycetes (Streptomyces spp.): major producers of antibiotics. Fungi (Penicillium, Cephalosporium): β-lactams.

Semi-synthetic Derivatives

Modification: chemical alteration of natural antibiotics. Objectives: improved potency, spectrum, pharmacokinetics, reduced resistance.

Fully Synthetic Antibiotics

Examples: sulfonamides, quinolones. Advantages: structural diversity, tailored specificity, scalable production.

Biosynthesis in Microorganisms

Secondary Metabolite Pathways

Antibiotics: secondary metabolites, non-essential for growth. Biosynthetic gene clusters encode enzymes for production.

Polyketide Synthases and Nonribosomal Peptide Synthetases

Complex multi-enzyme systems. Generate diverse antibiotic structures (e.g., erythromycin, vancomycin).

Regulation of Biosynthesis

Environmental factors: nutrient limitation, stress induce production. Genetic regulation: transcriptional activators/repressors.

Clinical Applications

Therapeutic Uses

Indications: respiratory, urinary tract, skin, gastrointestinal infections. Selection: based on pathogen, susceptibility, site of infection.

Prophylactic Use

Prevention: post-surgical infection, immunocompromised patients. Risk-benefit analysis crucial to avoid resistance.

Combination Therapy

Purpose: broaden spectrum, prevent resistance, synergistic effects. Examples: β-lactam + β-lactamase inhibitor.

Antibiotic Resistance

Mechanisms of Resistance

Enzymatic degradation (β-lactamases), target modification, efflux pumps, reduced permeability.

Genetic Basis

Resistance genes: plasmids, transposons, integrons facilitate horizontal transfer.

Impact on Public Health

Threat: multidrug-resistant pathogens. Consequences: increased morbidity, mortality, healthcare costs.

Resistance Mechanisms:1. Enzymatic inactivation (e.g. β-lactamase)2. Altered target sites (e.g. ribosomal mutations)3. Efflux pumps expelling drugs4. Reduced membrane permeability

Biotechnology in Antibiotic Production

Strain Improvement

Methods: mutagenesis, recombinant DNA technology. Goal: enhanced yield, stability.

Genetic Engineering

Techniques: gene cloning, pathway modification. Outcomes: novel antibiotics, optimized biosynthesis.

Fermentation Technology

Process: controlled microbial culture conditions. Parameters: pH, temperature, oxygenation optimized for maximal production.

Pharmacodynamics and Pharmacokinetics

Absorption and Distribution

Routes: oral, intravenous, intramuscular. Distribution: tissue penetration varies by antibiotic class.

Metabolism and Excretion

Metabolism: hepatic biotransformation common. Excretion: renal, biliary pathways.

Dosing Strategies

Parameters: minimum inhibitory concentration (MIC), therapeutic index. Strategies: time-dependent vs concentration-dependent killing.

Adverse Effects and Toxicity

Common Side Effects

Gastrointestinal disturbances (nausea, diarrhea), allergic reactions (rash, anaphylaxis).

Toxicity

Nephrotoxicity (aminoglycosides), ototoxicity, hepatotoxicity in select agents.

Management of Side Effects

Monitoring: renal function, liver enzymes. Dose adjustment and alternative therapies if required.

Future Perspectives and Challenges

Combating Resistance

Development: novel antibiotics, adjuvant therapies, resistance inhibitors.

Alternative Approaches

Phage therapy, antimicrobial peptides, CRISPR-based antimicrobials under investigation.

Regulatory and Economic Considerations

Challenges: high development cost, regulatory hurdles, incentivizing antibiotic innovation.

References

• Walsh, C.T., "Antibiotics: Actions, Origins, Resistance," ASM Press, 2003.
• Davies, J., Davies, D., "Origins and evolution of antibiotic resistance," Microbiol Mol Biol Rev, vol. 74, 2010, pp. 417-433.
• Demain, A.L., Fang, A., "The natural functions of secondary metabolites," Adv Biochem Eng Biotechnol, vol. 69, 2000, pp. 1-39.
• Ventola, C.L., "The antibiotic resistance crisis: part 1: causes and threats," P T, vol. 40, 2015, pp. 277-283.
• Chopra, I., Roberts, M., "Tetracycline antibiotics: mode of action, applications, molecular biology, and epidemiology of bacterial resistance," Microbiol Mol Biol Rev, vol. 65, 2001, pp. 232-260.